Comparative Pharmacology
Head-to-head clinical analysis: LIDOCATON versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCATON versus XYLOCAINE 4 PRESERVATIVE FREE.
LIDOCATON vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting the inward sodium current, thereby stabilizing cardiac membranes, decreasing automaticity, and increasing the fibrillation threshold. It also acts as a local anesthetic by reversibly blocking nerve impulse propagation.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
Lidocaine: Initial IV bolus 1-1.5 mg/kg, then IV infusion 1-4 mg/min. Adjust for arrhythmia suppression.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal half-life 1.5–2 hours (adults); prolonged in heart failure (up to 4–6 hours) or hepatic impairment (up to 8 hours).
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Renal: ~90% as metabolites (major metabolite 4-hydroxyxylidine) and ~10% unchanged. Biliary/fecal: <5%.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic